|
28 May 2020 |
Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
|
|
28 May 2020 |
FDA Accepts for Review Fresenius Kabi’s BLA Submission for Pegfilgrastim Biosimilar
|
|
28 May 2020 |
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
|
|
27 May 2020 |
Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers
|
|
26 May 2020 |
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
|
|
26 May 2020 |
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
|
|
26 May 2020 |
Biotest achieves significant milestone by completing phase I/III clinical trial with fibrinogen
|
|
25 May 2020 |
Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA
|
|
20 May 2020 |
Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
|
|
20 May 2020 |
Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
|
|
14 May 2020 |
Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
|
|
14 May 2020 |
DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study
|
|
14 May 2020 |
Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial
|
|
13 May 2020 |
Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
|
|
12 May 2020 |
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
|
|
08 May 2020 |
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
|
|
07 May 2020 |
Molecular Partners Confirms Ultra-Potent Inhibition of SARS-CoV-2 Live Virus by Anti-COVID-19 DARPin Candidates
|
|
05 May 2020 |
Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab
|
|
04 May 2020 |
Sanofi receives CHMP recommendation for approval of insulin aspart biosimilar
|
|
30 Apr 2020 |
Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
|
|
27 Apr 2020 |
Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer
|
|
27 Apr 2020 |
FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant
|
|
24 Apr 2020 |
Biomarck Announces, Phase 2a Clinical Trial Results of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)
|
|
21 Apr 2020 |
INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19
|
|
20 Apr 2020 |
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism
|
